antibody

Mouse Monoclonal (IgG2a) to Human c-Met

MBS245381

0.05 mL

495 USD

monoclonal

mouse

nonconjugated

Antibody

Mouse Monoclonal (IgG2a) to Human c-Met

c-Met

Anti-c-Met Antibody (Cytoplasmic Domain) IHC-plus; AUTS9; C-Met; HGF/SF receptor; HGFR; Met kinase; Proto-oncogene c-Met; Scatter factor receptor; SF receptor; HGF receptor; RCCP2; Tyrosine-protein kinase Met; Human c-Met

hepatocyte growth factor receptor isoform b; Hepatocyte growth factor receptor; hepatocyte growth factor receptor; SF receptor; HGF receptor; HGF/SF receptor; proto-oncogene c-Met; scatter factor receptor; tyrosine-protein kinase Met; met proto-oncogene tyrosine kinase; MET proto-oncogene, receptor tyrosine kinase; HGF/SF receptor; Proto-oncogene c-Met; Scatter factor receptor; SF receptor; Tyrosine-protein kinase Met

MET

c-Met

MET; MET; HGFR; AUTS9; RCCP2; c-Met; HGF receptor; SF receptor

MET_HUMAN

Monoclonal

IgG2a

Mouse

Human

1390

Recognizes c-Met.

Purified

PBS, pH 7.4, 1% BSA, 0.1% sodium azide.

1.14 mg/ml

Long term: -20 degree C; Short term: +4 degree C; Avoid freeze-thaw cycles.

Immunohistochemistry (IHC - Paraffin; IHC - Frozen)

IHC-Fr (1:50), IHC-P (10 ug/ml). Usage: Immunohistochemistry: was validated for use in immunohistochemistry on a panel of 21 formalin-fixed, paraffin-embedded (FFPE) human tissues after heat induced antigen retrieval in pH 6.0 citrate buffer. After incubation with the primary anti.

Target Species: Human. Immunogen Description: Synthetic peptide derived from cytoplasmic domain of human c-Met protein.

Immunogen Type: Synthetic peptide. Immunogen: c-Met antibody was raised against synthetic peptide derived from cytoplasmic domain of human c-Met protein. Antigen Modification: Cytoplasmic Domain

Family: Protein Kinase. Subfamily: HGF Receptor/MET

Met, an HGF Receptor/Met type protein kinase, is a cell-surface proto-oncogene that mediates the biological activities of hepatocyte growth factor. The protein is a disulfide-linked heterodimer comprised of two subunits: a 50 kD extracellular alpha subunit and a membrane-spanning 145 kD beta subunit that binds ligand. Met is an important regulator of cell proliferation and differentiation, organ regeneration, embryogenesis, and tumorogenesis.

42741655

NP_000236.2

NM_000245.2

P08581

85,745 Da

Adherens Junction Pathway (83070); Adherens Junction Pathway (481); Alpha6-Beta4 Integrin Signaling Pathway (198807); Arf6 Signaling Events Pathway (138034); Axon Guidance Pathway (83065); Axon Guidance Pathway (476); Axon Guidance Pathway (105688); Bacterial Invasion Of Epithelial Cells Pathway (149807); Bacterial Invasion Of Epithelial Cells Pathway (148661); Central Carbon Metabolism In Cancer Pathway (1059538)

The proto-oncogene MET product is the hepatocyte growth factor receptor and encodes tyrosine-kinase activity. The primary single chain precursor protein is post-translationally cleaved to produce the alpha and beta subunits, which are disulfide linked to form the mature receptor. Various mutations in the MET gene are associated with papillary renal carcinoma. Two transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Jul 2008]

Met: a proto-oncogenic receptor tyrosine kinase with high affinity for hepatocyte growth factor. The primary single chain precursor protein is post-translationally cleaved to produce the 45 kDa alpha- and 145 kDa beta-subunits, which are disulfide linked to form the mature receptor. Ligand-binding induces autophosphorylation at multiple tyrosines, which recruit several downstream signaling components, including Gab1, c-Cbl and PI3 kinase. Activating point mutations cause hereditary papillary renal carcinoma. Mutations also seen in sporadic renal cell carcinoma and childhood hepatocellular carcinoma. Upregulation in carcinomas and sarcomas correlates with metastasis and poor outcome. Some gastric carcinomas harbor a translocation that creates an activated TPR-Met fusion protein. A small molecule inhibitor (PHA-665752) shows an effect in gastric carcinoma xenografts. Inhibitors: SU11274, PHA-665752, mAbs. Two alternatively spliced human isoforms have been reported. Protein type: Protein kinase, TK; Kinase, protein; EC 2.7.10.1; Protein kinase, tyrosine (receptor); Membrane protein, integral; Oncoprotein; TK group; Met family. Chromosomal Location of Human Ortholog: 7q31. Cellular Component: cell surface; integral to plasma membrane; basal plasma membrane; integral to membrane; extracellular region; plasma membrane. Molecular Function: protein binding; protein-tyrosine kinase activity; protein phosphatase binding; hepatocyte growth factor receptor activity; ATP binding. Biological Process: axon guidance; skeletal muscle development; peptidyl-tyrosine phosphorylation; activation of MAPK activity; myoblast proliferation; protein amino acid autophosphorylation; myotube differentiation; muscle cell migration; hepatocyte growth factor receptor signaling pathway; glucose homeostasis; liver development; signal transduction; cell proliferation; cell surface receptor linked signal transduction; positive chemotaxis; branching morphogenesis of a tube; adult behavior; positive regulation of transcription from RNA polymerase II promoter; endothelial cell morphogenesis; brain development; placenta development. Disease: Hepatocellular Carcinoma; Renal Cell Carcinoma, Papillary, 1

0.05 mL

495 USD